Japanese Healthcare Industry: Focus on Companies Achieving Overseas Growth through Differentiated Products (UBS)
UBS released a report on the Japanese healthcare industry, highlights focusing on companies that have differentiated products and can achieve overseas growth.
UBS released a report on the Japanese healthcare industry, highlights focusing on companies that have differentiated products and can achieve overseas growth. The report covers M3, Terumo, Sysmex, Olympus and many other companies, and provides detailed financial forecasts. UBS pointed out that Japanese medical companies have huge room for growth in overseas markets, especially the United States, Europe and emerging markets. For example, Terumo's interventional therapy system and Sysmex's in vitro diagnostic business are globally competitive. What these companies have in common is that they have established moats in niche areas through continuous technological innovation. One-sentence conclusion: Against the backdrop of growing global healthcare spending and expanding demand in emerging markets, Japanese medical companies with world-leading technologies and differentiated product lines have the ability to grow through cycles and are high-quality choices for the theme of "going overseas." Positive/negative: Positive for companies with overseas competitiveness such as M3 (2413), Terumo (4543), Sysmex (6869), Olympus (7733). The market has certain expectations for the growth of these companies, but the possibility that their overseas businesses will continue to exceed expectations will determine the long-term performance of their stock prices. Catalysts: 1) Each company's overseas business revenue growth data in the second half of the year; 2) The approval and launch progress of new products in the European and American markets; 3) The impact of Japanese yen exchange rate fluctuations on the exchange gains of overseas revenue.